Clinical trial
A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
NCT00189813 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00189813 |
|---|---|
| Title | A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS) |
| Official title | A Randomized, Double-blind, Placebo-controlled Study to Investigate the Potential Efficacy, Safety and Tolerability of Different Oral Doses of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Astellas Pharma Europe B.V. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Irritable Bowel Syndrome |
| Intervention type | Drug |
| Interventions | YM060 |
| Enrollment | 691 |
| Start date | Mar 1, 2005 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Aug 28, 2014 |
| Countries | Bulgaria, Czechia, Estonia, Germany, Lithuania, Poland, Russia, Ukraine |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: